Pages that link to "Q38798344"
Jump to navigation
Jump to search
The following pages link to The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients (Q38798344):
Displayed 50 items.
- CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer (Q24318416) (← links)
- Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? (Q26748581) (← links)
- Biomarker development in MET-targeted therapy (Q26751332) (← links)
- Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells (Q30492361) (← links)
- A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer (Q33599860) (← links)
- Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients (Q33688558) (← links)
- Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures (Q33748638) (← links)
- Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas (Q34254343) (← links)
- Targeting MET Amplification as a New Oncogenic Driver. (Q34309927) (← links)
- Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells (Q35051630) (← links)
- AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells (Q35188254) (← links)
- c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target (Q35650167) (← links)
- MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. (Q35694610) (← links)
- Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation (Q35770249) (← links)
- Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit (Q35858331) (← links)
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? (Q35896530) (← links)
- Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients (Q35926926) (← links)
- Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer (Q35983145) (← links)
- Genomics of lung cancer may change diagnosis, prognosis and therapy (Q36084693) (← links)
- Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples (Q36261427) (← links)
- Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy (Q36318551) (← links)
- Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. (Q36439444) (← links)
- Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas (Q36583435) (← links)
- Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis (Q36713414) (← links)
- c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer (Q36812161) (← links)
- Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy (Q36828371) (← links)
- Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer (Q36878125) (← links)
- Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients (Q37080964) (← links)
- HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration (Q37158288) (← links)
- Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer (Q37209597) (← links)
- Following up tumour angiogenesis: from the basic laboratory to the clinic (Q37230680) (← links)
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. (Q37321772) (← links)
- The function, proteolytic processing, and histopathology of Met in cancer (Q37621003) (← links)
- Clinical implications of MET gene copy number in lung cancer (Q37690299) (← links)
- Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers (Q37730020) (← links)
- c-MET as a potential therapeutic target and biomarker in cancer (Q37962905) (← links)
- Targeting MET in cancer: rationale and progress (Q37978193) (← links)
- Developing biomarkers to predict benefit from HGF/MET pathway inhibitors (Q38150768) (← links)
- MET and Small-Cell Lung Cancer (Q38260120) (← links)
- Emerging drugs for squamous cell lung cancer (Q38306880) (← links)
- Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification (Q38370754) (← links)
- cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance (Q38393333) (← links)
- Prognostic model of stage II non-small cell lung cancer by a discriminant analysis of the immunohistochemical protein expression (Q38435135) (← links)
- Prognostic and predictive value of MET deregulation in non-small cell lung cancer (Q38493294) (← links)
- TIMPs: versatile extracellular regulators in cancer (Q38785433) (← links)
- Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. (Q38982398) (← links)
- Lung Cancer Biomarkers (Q39027394) (← links)
- Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer (Q39061272) (← links)
- Activation of HGF/c-Met signaling by ultrafine carbon particles and its contribution to alveolar type II cell proliferation (Q39412120) (← links)
- Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer (Q39503071) (← links)